On Jul. 19, 2022, Gilead Sciences and the European Commission announced a new joint procurement agreement (JPA) that ensured continued rapid and equitable access to Vekluryﾮ (remdesivir) for participating Member States across the European Union and European Economic Area.

The agreement covers purchases of Veklury over the next twelve months and had the option to be extended for an additional six months. It followed the expiration of the original JPA agreement, the first for a COVID-19 therapeutic, signed in October 2020.